InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer's and Parkinson's Pipeline, Launches Pivotal Phase 3 Trial

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.